BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 9808546)

  • 1. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.
    Woolfrey AE; Gooley TA; Sievers EL; Milner LA; Andrews RG; Walters M; Hoffmeister P; Hansen JA; Anasetti C; Bryant E; Appelbaum FR; Sanders JE
    Blood; 1998 Nov; 92(10):3546-56. PubMed ID: 9808546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
    Greinix HT; Keil F; Brugger SA; Reiter E; Linkesch W; Lechner K; Schneider B; Dieckmann KU; Fischer G; Schwarzinger I; Haas O; Hinterberger W; Mannhalter C; Geissler K; Hocker P; Jager U; Kalhs P
    Ann Hematol; 1996 Feb; 72(2):53-9. PubMed ID: 8597607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
    Kanakry CG; Tsai HL; Bolaños-Meade J; Smith BD; Gojo I; Kanakry JA; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Powell JD; Pratz KW; DeZern AE; Showel MM; McDevitt MA; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Blood; 2014 Dec; 124(25):3817-27. PubMed ID: 25316679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
    Casper J; Camitta B; Truitt R; Baxter-Lowe LA; Bunin N; Lawton C; Murray K; Hunter J; Pietryga D; Garbrecht F
    Blood; 1995 May; 85(9):2354-63. PubMed ID: 7727769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
    Castro-Malaspina H; Jabubowski AA; Papadopoulos EB; Boulad F; Young JW; Kernan NA; Perales MA; Small TN; Hsu K; Chiu M; Heller G; Collins NH; Jhanwar SC; van den Brink M; Nimer SD; O'Reilly RJ
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):458-68. PubMed ID: 18342789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
    Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unrelated donor marrow transplantation in children.
    Balduzzi A; Gooley T; Anasetti C; Sanders JE; Martin PJ; Petersdorf EW; Appelbaum FR; Buckner CD; Matthews D; Storb R; Sullivan KM; Hansen JA
    Blood; 1995 Oct; 86(8):3247-56. PubMed ID: 7579422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
    Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.